Greater Height Tied to Higher Risk of Venous Thromboembolism

This article originally appeared here.
Share this content:
Greater Height Tied to Higher Risk of Venous Thromboembolism
Greater Height Tied to Higher Risk of Venous Thromboembolism

MONDAY, Sept. 11, 2017 (HealthDay News) -- Height is an independent predictor of venous thromboembolism (VTE), according to a study published online Sept. 5 in Circulation: Cardiovascular Genetics.

Bengt Zöller, M.D., Ph.D., from Malmö University Hospital in Sweden, and colleagues used data from Swedish national registries to identify 1,610,870 male conscripts born between 1951 and 1992 without previous VTE. They were followed from enlistment (1969-2010) until 2012. Separately, 1,093,342 first-time pregnant women from the medical birth register, without previous VTE, were followed from first pregnancy (1982-2012) until 2012. All full-sibling pairs discordant for height were identified.

The researchers found that compared with the tallest women (>185 cm) and men (>190 cm), there was a graded decreased risk by lower height for both men and women. The risk was lowest in those with the shortest stature (<155 for women and <160 cm for men): hazard ratios, 0.31 and 0.35, respectively. There was also a graded association in the co-sibling design comparing siblings with different degrees of discordance for height (reference was the taller sibling): ≥10 cm difference between brothers (HR, 0.69) and sisters (HR, 0.65).

"The use of sibling pairs reduces the likelihood that familial confounding explains the results. The findings are important for the understanding of the pathogenesis of VTE," conclude the authors.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »